期刊文献+

右旋糖酐铁治疗肾性贫血的疗效观察

Observation on Curative Effect of Iron Dextran in Treatment of Renal Anaemia
下载PDF
导出
摘要 目的探讨静脉补铁治疗血液透析(HD)患者肾性贫血的疗效和不良反应。方法选择78例HD患者,分为静脉补铁组和口服补铁组,每组39例。静脉补铁组:每次透析结束前1h注射100mg右旋糖酐铁,从透析器静脉端输入,时间维持1h。口服补铁组:琥珀酸亚铁(速立菲)200mg。每日3次,连续口服2个月。两组同时使用基因重组人红细胞生成素(rHuEPO)100~150U/(kg·w)皮下注射。比较两组患者贫血治疗的效果和副作用。结果治疗后两组患者贫血均改善。其中静脉补铁组的血红蛋白(Hb)、红细胞压积(Hct)及转铁蛋白饱和度(TSAT)较口服补铁组显著升高,而不良反应发生率较口服补铁组降低。结论静脉注射右旋糖酐铁可作为血透伴缺铁患者理想补铁方式,配合rHuEPO治疗贫血,疗效明显优于口服补铁,且不良反应发生率低。
出处 《河南科技大学学报(医学版)》 2007年第4期284-285,共2页 Journal of Henan University of Science & Technology:Medical Science
  • 相关文献

参考文献8

  • 1Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin[J]. Kidney Int,1996,50:1694 - 1699.
  • 2赵晋媛 袁利.静脉注射右旋糖酐氢氧化铁对血透患者肾性贫血的疗效观察.中华现代内科学杂志,2006,3(10):1109-1111.
  • 3王海燕.肾脏病学[M]第2版[M].北京:人民卫生出版社,1998.103-104.
  • 4Fishbane S, Mittal SK, Maesala JK. Beneficial effets of iron therapy in renal failure patients on hemodialysis [ J ]. Kidney Int, 1999,55 ( Suppl 69 ) :67 - 70.
  • 5National Kidney Foundation. K/DOQI clinical pratice guidelines for anemia of chronic kidney disease,2000[J]. Am J Kidney Dis, 2001,37:182 -238.
  • 6田秋菊,徐令华.终末期肾脏病患者的铁代谢紊乱及铁剂治疗[J].医学综述,1999,5(6):276-277. 被引量:2
  • 7Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin [J]. Curr Opinion Nephrol Hypertens, 1994,3:620.
  • 8王莉,叶长宁,王芳,何强,李贵森.静脉补铁和口服补铁对肾性贫血的治疗比较[J].四川医学,2002,23(11):1111-1113. 被引量:10

二级参考文献6

  • 1[1]Teehan B, et al. Hematologic and physiologic studies during correction of anemia with recombinant human erythropoietin in predialysis patients. Trans-plant Proc, 1996,212:63
  • 2[2]Harnett JD, et al. Congestive heart failure in dialysis patients:prevalence, in-cidence,prognosis and risk factors. Kidney Int, 1995,47:884
  • 3[3]Vanholder R, et al. Contributing factors to the inhibition of phagocytosis inhemodialyzed patients. Kidney Int, 1993,44:208
  • 4[4]Lowrie EG, et al. The relative contribution of measured variables to death riskamong hemodialysis patients, in Friedman E A: Death on hemo dialysis: pre-ventable or inevitable? Boston, MA, Kluwer academic Publisher, 1994,121
  • 5[5]US Renal Date System: The USRD Dialysis Morbidity and Mortality Study(Wave 1). in National Instiutes of Health, National Institute Diabetes and Digestive and Kidney Disease: US renal Date System 1996 Annual Date Report.Bethesda, MD, 1996,45
  • 6[6]Mizuguchi T, et al. Serum transferrin receptor level as an index of the response to erythropoietin therapy for anemia in pre-dialysis patients with chronic renal failure. Nippon Jinzo Gakkai Shi, 1997 Jul,39(5):497

共引文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部